Prostaglandin E1 prevents increased lung microvascular permeability during intravascular complement activation in sheep.
Prostaglandin E1 (PGE1) inhibits a variety of functions of activated neutrophils including respiratory burst, release of leukotriene B4, and adherence to endothelial cells. To determine if PGE, alters the pathophysiology of complement-induced lung vascular injury, experiments were conducted in anesthetized sheep with lung lymph fistulas given a 1-hour infusion of zymosan-activated plasma. PGE1 (30 ng/min/kg) or its saline vehicle was infused intravenously for 90 minutes beginning 30 minutes before the infusion of activated plasma. PGE1 had no effect on leukocyte count, the initial hypoxemia and thromboxane A2 release, or the development of acute pulmonary hypertension. However, PGE1 prevented steady-state increases in lung lymph flow that in vehicle-treated sheep signaled an increase in lung microvascular permeability. Furthermore, extraction of PGE1 by pulmonary endothelial cells was unaffected by the infusion of activated plasma. We propose that PGE1 prevented the increase in lung vascular permeability by inhibiting adherence of activated neutrophils to endothelial cells.
D000527:Alprostadil / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001790:Blood Physiological Phenomena; D002199:Capillary Permeability / Q000187:drug effects*; D002448:Cell Adhesion; D003167:Complement Activation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D008196:Lymph / Q000502:physiology; D008297:Male; D009504:Neutrophils / Q000502:physiology; D011652:Pulmonary Circulation / Q000187:drug effects*; D012756:Sheep; D012965:Sodium Chloride / Q000494:pharmacology; D013928:Thromboxane A2 / Q000378:metabolism; D015054:Zymosan / Q000494:pharmacology
D012965:Sodium Chloride; D013928:Thromboxane A2; D015054:Zymosan; D000527:Alprostadil